353 related articles for article (PubMed ID: 32398261)
1. Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma.
Xu B; Qin T; Yu J; Giordano TJ; Sartor MA; Koenig RJ
J Biol Chem; 2020 Jun; 295(26):8834-8845. PubMed ID: 32398261
[TBL] [Abstract][Full Text] [Related]
2. miR-142-3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1.
Colamaio M; Puca F; Ragozzino E; Gemei M; Decaussin-Petrucci M; Aiello C; Bastos AU; Federico A; Chiappetta G; Del Vecchio L; Torregrossa L; Battista S; Fusco A
J Clin Endocrinol Metab; 2015 Jan; 100(1):E59-69. PubMed ID: 25238203
[TBL] [Abstract][Full Text] [Related]
3. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma.
Samimi H; Haghpanah V; Irani S; Arefian E; Sohi AN; Fallah P; Soleimani M
Daru; 2019 Jun; 27(1):1-7. PubMed ID: 31077090
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of HCP5 exerts tumor-suppressive functions by up-regulating tumor suppressor miR-128-3p in anaplastic thyroid cancer.
Chen J; Zhao D; Meng Q
Biomed Pharmacother; 2019 Aug; 116():108966. PubMed ID: 31102936
[TBL] [Abstract][Full Text] [Related]
5. Genomic amplification of long noncoding RNA HOTAIRM1 drives anaplastic thyroid cancer progression via repressing miR-144 biogenesis.
Zhang L; Zhang J; Li S; Zhang Y; Liu Y; Dong J; Zhao W; Yu B; Wang H; Liu J
RNA Biol; 2021 Apr; 18(4):547-562. PubMed ID: 32951513
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1.
Gou L; Zou H; Li B
Cancer Biol Ther; 2019; 20(11):1355-1365. PubMed ID: 31500506
[TBL] [Abstract][Full Text] [Related]
7. LncRNA H19 Influences Cellular Activities via the miR-454-3p/BHLHE40 Axis in Anaplastic Thyroid Carcinoma.
Wu Y; Yang J; Zhang H; Cheng J; Lei P; Huang J
Horm Metab Res; 2024 May; 56(5):392-399. PubMed ID: 38052232
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA UCA1 promotes anaplastic thyroid cancer cell proliferation via miR‑135a‑mediated c‑myc activation.
Wang Y; Hou Z; Li D
Mol Med Rep; 2018 Sep; 18(3):3068-3076. PubMed ID: 30015867
[TBL] [Abstract][Full Text] [Related]
9. miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression.
Sheng W; Chen Y; Gong Y; Dong T; Zhang B; Gao W
Oncol Rep; 2016 Dec; 36(6):3387-3396. PubMed ID: 27779717
[TBL] [Abstract][Full Text] [Related]
10. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
11. Thyroid Follicular Cell Loss of Differentiation Induced by MicroRNA miR-17-92 Cluster Is Attenuated by CRISPR/Cas9n Gene Silencing in Anaplastic Thyroid Cancer.
Fuziwara CS; Saito KC; Kimura ET
Thyroid; 2020 Jan; 30(1):81-94. PubMed ID: 31578932
[No Abstract] [Full Text] [Related]
12. MicroRNA 483-3p targets Pard3 to potentiate TGF-β1-induced cell migration, invasion, and epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Zhang X; Liu L; Deng X; Li D; Cai H; Ma Y; Jia C; Wu B; Fan Y; Lv Z
Oncogene; 2019 Jan; 38(5):699-715. PubMed ID: 30171257
[TBL] [Abstract][Full Text] [Related]
13. MiR-125b inhibits anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD.
Bu Q; You F; Pan G; Yuan Q; Cui T; Hao L; Zhang J
Biomed Pharmacother; 2017 Apr; 88():443-448. PubMed ID: 28122310
[TBL] [Abstract][Full Text] [Related]
14. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression.
Yan P; Su Z; Zhang Z; Gao T
Int J Oncol; 2019 Nov; 55(5):988-1002. PubMed ID: 31485599
[TBL] [Abstract][Full Text] [Related]
15. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
16. Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas.
Borbone E; Troncone G; Ferraro A; Jasencakova Z; Stojic L; Esposito F; Hornig N; Fusco A; Orlando V
J Clin Endocrinol Metab; 2011 Apr; 96(4):1029-38. PubMed ID: 21289264
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Highly Expressed microRNA miR-146b with CRISPR/Cas9n Gene Editing System in Thyroid Cancer.
Santa-Inez DC; Fuziwara CS; Saito KC; Kimura ET
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360757
[TBL] [Abstract][Full Text] [Related]
18. Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance.
Selemetjev SA; Savin SB; Paunovic IR; Tatic SB; Cvejic D
Wien Klin Wochenschr; 2015 May; 127(9-10):337-44. PubMed ID: 25471003
[TBL] [Abstract][Full Text] [Related]
19. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Smith N; Nucera C
J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
[TBL] [Abstract][Full Text] [Related]
20. Targeted inhibition of long non-coding RNA H19 blocks anaplastic thyroid carcinoma growth and metastasis.
Zhang H; Yu Y; Zhang K; Liu X; Dai Y; Jiao X
Bioengineered; 2019 Dec; 10(1):306-315. PubMed ID: 31299871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
